Could a diabetes injection help early Parkinson's patients?
NCT ID NCT03439943
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested whether lixisenatide, a daily injection already used for diabetes, could slow the worsening of motor symptoms in 156 people with early Parkinson's disease. Participants received either the drug or a placebo for 12 months, alongside their usual Parkinson's medications. The study measured changes in movement disability to see if lixisenatide has a disease-modifying effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lixisenatide (a daily injection used for diabetes, repurposed for Parkinson's)
What this could lead to
If successful, this could point toward a treatment that slows the worsening of movement problems in early Parkinson's disease.
What could go wrong
This is a small, early-stage (Phase 2) proof-of-concept trial, so results may not confirm benefit. The drug can cause nausea and other side effects, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse
Toulouse, 31000, France
-
Creteil- Henri Mondor Hospital
Créteil, France
-
Pitié Salpêtrière Hospital
Paris, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Besancon
Besançon, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Caen
Caen, France
-
University Hospital of Clermont-Ferrand
Clermont-Ferrand, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Limoges
Limoges, France
-
University Hospital of Lyon
Lyon, France
-
University Hospital of Marseille
Marseille, France
-
University Hospital of Montpellier
Montpellier, France
-
University Hospital of Nancy
Nancy, France
-
University Hospital of Nantes
Nantes, France
-
University Hospital of Nice
Nice, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Rennes
Rennes, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Strasbourg
Strasbourg, France